Info corso

crediti ECM
9
Chiusura ECM
martedì 11/03/2025 23:59
Codice ECM
7194-438081
Destinatari

Biologo
Infermiere
Farmacista
Medico Chirurgo:
Ematolgia; Medicina Interna; Oncologia; Radioterapia

Modalità di
partecipazione
  • RES presso NH Hotel Trieste

    Corso Camillo Benso Conte di Cavour, 7
    34132 - Trieste (ITA)

Help desk
Per informazioni contattare l'indirizzo email: ematologia@meetingsrl.eu
Tel: 0432 1790500 – 347 4541841

Programma del corso

FRIDAY | March 7, 2025

13:00-13:30Get together and Welcoming Address
Francesco Zaja, UCO Ematologia Trieste
Roberto Di Lenarda, Rector Trieste University

13:30-15:00SESSION I | Myeloid Neoplasms-Biology

Chairmen:Heinz Sill (Graz - AUT)
Matevz Skerget (Ljubljana - SVN)

13:30-13:45NGS in acute myeloid leukemia - impact on therapy choice and prognosis
Mirta Mikulic (Zagreb - CRO)

13:45-14:00Gene expression analysis of autophagy markers in primary and secondary myelofibrosis
Marin Medjugorac (Zagreb - CRO)

14:00-14:15TP53 aberrations in myeloid neoplasms
Dutta Sayantanee (Graz - AUT)

14:15-14:30Leukemia Biobanking and its use for translational research
Armin Zebisch (Graz - AUT)

14:30-15:00Myeloid Neoplasms: Round Table Discussion, Common Interests & Potential Collaborations

15:00-16:45SESSION II | Myeloid Neoplasms-Clinic

Chairmen:Mario Tiribelli (Udine - ITA)
Andreas Reinisch (Graz - AUT)

15:00-15:15FLAG/FLAG-Idain R/R AML and new treatment modalities- single center experience
Sasa Anzej-Doma (Ljubljana - SVN)

15:15-15:30Non-classical risk factors for cardiovascular disease in MPN
Matjaz Sever (Ljubljana - SVN)

15:30-15:45Leveraging inflammation to combat acute myeloid leukemia
Philipp Jost (Graz - AUT)

15:45-16:00Clinical and molecular determinants of vascular events and progression in essential thrombocythemia
Luca Tosoni (Udine - ITA)

16:00-16:15Prognostic impact of mutational landscape on outcome to Venetoclax plus HMA in naïve unfit AML patients: a “real-life” experience
Eleonora De Bellis (Trieste - ITA)

16:15-16:45Myeloid Neoplasma: Round Table Discussion, Common Interests & Potential Collaborations

16:45-17:15Coffee break

17:15-17.35LECTURE I
Bispecific antibodies in the treatment of B-cell lymphomas: state of art

Umberto Vitolo (Candiolo - ITA)

17:35-19:20SESSION III | Lymphoid Neoplasms

Chairmen:Igor Aurer (Zagreb - CRO)
Samo Zver (Ljubljana - SVN)

17:35-17:50Venetoclax for treatment of CLL
Dino Dujmovic (Zagreb - CRO)

17:50-18:05Our experience with ixazomib in the treatment of myeloma
Ida Ivek (Zagreb - CRO)

18:05-18:20Teclistamab plus autologous lymphocytes in R/R MM; TALIM study
Francesco Zaja (Trieste - ITA)

18:20-18:35TCL and JAK2 mutation: case presentation
Aleksandar Boskovic (Ljubljana - SVN)

18:35-18:50The Flavonoid Brusatol Induces Apoptosis in Aggressive Lymphoma Cells and Exhibits Synergic Effect with Venetoclax
Alexander Deutsch (Graz - AUT)

18:50-19:20Lymphoid Neoplasms: Round Table Discussion, Common Interests & Potential Collaborations

SATURDAY | March 8, 2025
08:30-10:00SESSION IV | Benign Hematology & General Topics in Hematology

Chairmen:Francesco Zaja (Trieste - ITA)
Drazen Pulanic (Zagreb - CRO)

08:30-08:45Treatment of bleeding in a patient with von Willebrand disease and inhibitors to vWF
Ena Rankovic (Zagreb - CRO)

08:45-09:00ITP: from biology to new target therapies
Elisa Lucchini (Trieste - ITA)

09:00-09:15Secondary Hemophagocytic Lymphohistiocytosis and Hyperinflammation in Infectious Diseases - An underestimated Topic
Stefan Hatzl (Graz - AUT)

09:15-09:30Approach to and management of non-clonal erythrocytosis
Irena Zupan (Ljubljana - SVN)

09:30-10:00Benign Hematology & General Topics in Hematology: Round Table Discussion, Common Interests & Potential Collaborations

10:00-10:30Coffee break

10:30-10:50LECTURE II
Where are we moving?

Giorgio Minotti (Rome - ITA)

10:50-12:50SESSION V | Cellular Therapy (CAR-T, alloHSCT)

Chairmen:Renato Fanin (Udine - ITA)
Hildegard Greinix (Graz - AUT)

10:50-11:05CMV reactivation post alloHSCT in the era of prophylactic therapy
Lana Desnica (Zagreb - CRO)

11:05-11:20CAR-T cell blood level monitoring
Katarina Rebersek (Ljubljana - SVN)

11:20-11:35CAR-T patients’ monitoring: the laboratory side
Eleonora Toffoletti (Udine - ITA)

11:35-11:50Spatial distribution of immune cells in patients with steroid-refractory graftversus-host disease
Lukas Gaksch (Graz - AUT)

11:50-12:05Endothelial damage in aGvHD
Novak Polona (Ljubljana - SVN)

12:05-12:20What’s going on in allogeneic transplantation and cellular therapies: the Udine experience
Marta Lisa Battista (Udine - ITA)

12:20-12:50Cellular Therapy: Round Table Discussion, Common Interests & Potential Collaborations

12:50-13:00Closing remarks
Francesco Zaja (Trieste - ITA)

Presentazione del corso

In these last decades there has been a continuous evolution of our knowledge in the biology, pathophysiology, diagnostic classification and treatment of many benign and malignant blood diseases. New therapeutic opportunities based on antigenic or molecular target have revolutionized the approach to patients. In particular, CAR-T cell and bispecific antibodies are now available in clinical practice for the treatment of patients with B-cell lymphoma, multiple myeloma and lymphoblastic leukemia The Alpe Adria meeting is aimed to be an academic scientific appointment where to discuss and compare the results of each Institution in different fields of hematology and the chance to offer new inter-institutional collaborations.

Comunicazioni

08/01/2025 How to register

The congress is aimed at the centers that are part of the ALPE ADRIA area: Italy, Slovenia, Croatia and Austria.
Four places are reserved for each center.
Please send any registration request to the following email address:
ematologia@meetingsrl.eu

MEETING SRL
Provider ECM n. 7194
Via Villalta 32, 33100 Udine
+39 0432 1790500
+39 0432 1790504
+39 347 4541841
info@meetingsrl.eu
www.meetingsrl.eu

ecm.meetingsrl.eu è la piattaforma ECM di MEETING srl su cui sono pubblicati i corsi ECM accreditati per operatori sanitari.

Engineered by